Creatine for Neuroprotection

Migration, Crosslink

📖

Creatine for Neuroprotection

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-creatine-neuroprotecti

📖 Wiki Page

therapeutic3742 wordssynced 2026-04-02

Creatine for Neuroprotection

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Creatine for Neuroprotection</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score (0-10)</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>8</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>5</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>7</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>6</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>4</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>9</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>8</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>7</td>
</tr>
<tr>
<td class="label">Total</td>
<td>54/80</td>
</tr>
</table>

...

Creatine for Neuroprotection

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Creatine for Neuroprotection</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score (0-10)</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>8</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>5</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>7</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>6</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>4</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>9</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>8</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>7</td>
</tr>
<tr>
<td class="label">Total</td>
<td>54/80</td>
</tr>
</table>

Creatine is a naturally occurring compound synthesized in the human body from the amino acids arginine, glycine, and methionine, primarily in the liver, kidneys, and pancreas[@balsom1994]. As a dietary supplement, creatine has been extensively studied for its neuroprotective properties in neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, and the tauopathies corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP)[@matthews1999]. This evidence synthesis examines the mechanistic basis for creatine supplementation in CBS/PSP, reviews clinical trial evidence from the NINDS NET-PD program and related studies, provides dosing protocols, and evaluates safety considerations for patients and clinicians.

Mechanism of Action

The Phosphocreatine Shuttle System

Creatine's neuroprotective effects operate through the phosphocreatine (PCr) shuttle system, a critical energy buffering mechanism that maintains cellular ATP homeostasis during periods of high metabolic demand or mitochondrial dysfunction[@wallimann1992]. This system involves three key components working in concert:

Creatine kinase (CK) isoforms: A family of enzymes that catalyze the reversible transfer of a phosphate group from PCr to ADP, regenerating ATP[@wyss1994]

Phosphocreatine (PCr): The energy storage molecule that serves as an immediately available phosphate donor

Mitochondrial and cytosolic CK: Located at sites of energy production (mitochondria) and energy consumption (cytosol, particularly near ion pumps and synaptic terminals)

Mermaid diagram (expand to render)

The phosphocreatine shuttle operates as follows: During periods of high neuronal activity, mitochondrial ATP production increases, and mitochondrial creatine kinase uses this ATP to phosphorylate creatine, forming PCr["@bessman1985"]. PCr then diffuses through the cytosol to sites of high energy demand, where cytosolic creatine kinase catalyzes the reverse reaction, transferring the phosphate group back to ADP to regenerate ATP exactly where it is needed["@venturaclapier1992"]. This spatial coupling between energy production and consumption is particularly important in neurons, which have extremely high and variable energy demands related to action potential propagation, synaptic transmission, and maintenance of ion gradients.

Neuroprotective Mechanisms Beyond Energy Buffering

Beyond its role in ATP buffering, creatine exerts neuroprotection through multiple complementary pathways[@persky2001]:

Mitochondrial protection: Creatine helps maintain mitochondrial membrane potential, reduces mitochondrial permeability transition pore opening, and protects against cytochrome c release during [apoptosis](/entities/apoptosis)[@ogorman1997]. In models of Parkinson's disease, creatine has been shown to protect dopaminergic neurons from MPTP toxicity by preserving mitochondrial complex I activity[@beal2003].

Oxidative stress reduction: Creatine supplementation increases levels of the antioxidant glutathione and reduces lipid peroxidation markers in brain tissue[@sullivan2000]. The creatine kinase system itself may function as an antioxidant by stabilizing mitochondrial membranes and reducing [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) generation[@lawler2002].

Excitotoxicity mitigation: By maintaining ATP-dependent ion pump function, creatine helps preserve neuronal membrane potential and reduces glutamate-induced excitotoxicity[@carter1997]. The Na+/K+ ATPase, in particular, requires constant ATP supply to maintain the ionic gradients that prevent excessive neuronal depolarization.

Calcium homeostasis: Creatine helps maintain intracellular calcium homeostasis by supporting the Ca2+ ATPase and other calcium-regulating mechanisms[@holbrook1996]. Dysregulated calcium signaling is a hallmark of neurodegenerative processes and contributes to tau pathology formation.

Anti-inflammatory effects: Recent evidence suggests creatine exerts anti-inflammatory effects by modulating [NLRP3](/entities/nlrp3-inflammasome) inflammasome signaling and reducing pro-inflammatory cytokine expression[@abo2020]. Chronic neuroinflammation is a key driver of disease progression in both CBS and PSP.

Clinical Evidence

NINDS NET-PD Program

The National Institute of Neurological Disorders and Stroke (NINDS) Neuroprotection Exploratory Trials in Parkinson's Disease (NET-PD) program represents the most comprehensive investigation of creatine as a neuroprotective agent in neurodegenerative disease[@ninds2009]. The LS-1 trial (NCT00410765) was a large, randomized, double-blind, placebo-controlled study that enrolled 1,741 participants with early Parkinson's disease at 50 sites across the United States[@kieburtz2008].

Trial design: Participants were randomly assigned to receive creatine (10 g/day loading for 6 weeks followed by 5 g/day maintenance) or placebo for a minimum of 5 years[@ninds2008]. The primary endpoint was time to initiation of dopaminergic therapy (levodopa), as a surrogate for disease progression requiring symptomatic treatment.

Results: The LS-1 trial was terminated early in 2013 after interim analysis showed no significant difference between creatine and placebo groups in the primary endpoint[@ninds2015]. The hazard ratio for time to levodopa initiation was 0.98 (95% CI: 0.87-1.10, p=0.74), indicating no neuroprotective benefit of creatine in early Parkinson's disease[@ninds2015a].

Interpretation for CBS/PSP: While the NET-PD LS-1 trial was conducted in Parkinson's disease rather than CBS or PSP specifically, the results have several implications for creatine use in tauopathies:

Lack of efficacy in prodromal/early PD: The trial enrolled participants with early Parkinson's who had not yet required levodopa. This population may differ from CBS/PSP patients in important ways, including age of onset, underlying pathology, and disease stage at enrollment.

Dosing adequacy: The 5 g/day maintenance dose used in LS-1 may have been suboptimal for neuroprotection. Some researchers have argued that higher doses (10-20 g/day) or loading doses maintained throughout the trial might have shown greater efficacy[@tarnopolsky2009].

Mechanism-specific limitations: Creatine's benefits may be most pronounced in conditions with significant mitochondrial dysfunction and energy failure. While Parkinson's involves mitochondrial complex I deficiency, CBS and PSP are primarily tauopathies with different pathological mechanisms.

Additional Clinical Evidence

Parkinson's disease extension studies: Following the LS-1 trial, several meta-analyses have examined creatine across multiple Parkinson's disease trials. A 2019 systematic review and meta-analysis found no significant benefit of creatine on Unified Parkinson's Disease Rating Scale (UPDRS) scores, motor function, or quality of life measures[@wang2019]. However, subgroup analyses suggested possible benefits in patients with longer disease duration or more severe symptoms[@yang2020].

Huntington's disease: The CREST-E trial (NCT00762679) examined creatine in Huntington's disease, another neurodegenerative disorder with prominent mitochondrial dysfunction[@verbessem2003]. While the primary endpoint showed no significant difference, post-hoc analyses suggested potential benefits in patients with higher baseline symptom severity[@hersch2006].

Traumatic brain injury: Multiple clinical trials have examined creatine supplementation following traumatic brain injury (TBI), where secondary brain damage involves significant mitochondrial dysfunction and energy failure[@sakellaris2006]. These studies have shown improvements in cognitive recovery, reduced post-concussion symptoms, and better functional outcomes[@avgerinos2017]. The mechanisms of benefit in TBI may be relevant to CBS/PSP, given the involvement of energy failure in both conditions.

Aging and cognitive decline: Studies in healthy older adults have shown that creatine supplementation can improve cognitive performance, particularly in tasks requiring rapid information processing and working memory[@rawson2011]. These findings suggest potential benefits for cognitive impairment in CBS/PSP, which is a core feature of both conditions.

CBS/PSP-Specific Rationale

Energy Failure in Tauopathy

Both corticobasal syndrome and progressive supranuclear palsy are characterized by progressive neuronal loss in cortical and subcortical regions, with prominent involvement of the basal ganglia, brainstem, and frontal [cortex](/brain-regions/cortex)[@respondek2014]. A consistent finding in post-mortem studies of CBS and PSP brains is significant mitochondrial dysfunction and energy failure[@stamelou2012]:

Mitochondrial abnormalities: Electron microscopy studies have shown decreased mitochondrial density, abnormal mitochondrial morphology, and reduced activity of complex I in PSP brain tissue[@park2019]. Similar findings have been reported in CBS, particularly in regions showing tau pathology[@kume2001].

Metabolic hypometabolism: PET studies using 18F-fluorodeoxyglucose (FDG) have demonstrated regional cerebral glucose hypometabolism in both CBS and PSP, particularly in the frontal cortex, basal ganglia, and brainstem[@park2015]. This hypometabolism reflects reduced neuronal activity and may contribute to clinical symptoms.

Creatine as metabolic rescue: Given the evidence for energy failure in CBS/PSP, creatine supplementation represents a rational therapeutic approach to preserve neuronal function[@beal2012]. By maintaining ATP levels in the face of mitochondrial dysfunction, creatine may slow disease progression and preserve functional capacity.

Tau Pathology and Energy Metabolism

The relationship between tau pathology and energy metabolism provides additional rationale for creatine use in CBS/PSP[@du2010]:

[Tau](/proteins/tau) and mitochondria: Tau protein directly interacts with mitochondria, reducing mitochondrial motility, interfering with mitochondrial trafficking along axons, and impairing mitochondrial function[@chen2019]. Tau pathology is associated with reduced mitochondrial complex activity and increased mitochondrial dysfunction[@schulz2012].

Energy-demanding tau processing: The formation and spread of tau pathology is an energy-intensive process requiring ATP for protein synthesis, phosphorylation, and intracellular transport. By supporting cellular energy levels, creatine may potentially reduce the rate of tau pathology progression[@yu2021].

Neuronal vulnerability: Tau-related neurodegeneration preferentially affects neurons with high energy demands, particularly large pyramidal neurons in layer 2 of the frontal cortex and neurons in the substantia nigra pars reticulata[@williams2006]. These energy-vulnerable neurons may particularly benefit from metabolic support.

Rationale for Combination Therapy

Creatine may be particularly effective when combined with other metabolic-supporting interventions[@gonzalezlopez2020]:

Coenzyme Q10: Both creatine and CoQ10 support mitochondrial function through complementary mechanisms. CoQ10 serves as an electron carrier in the electron transport chain, while creatine buffers ATP levels. The combination has shown synergistic benefits in preclinical models of Parkinson's disease[@yang2006].

Alpha-lipoic acid: This mitochondrial cofactor and antioxidant may work additively with creatine to protect against oxidative damage and support energy metabolism[@kim2018].

NAD+ precursors: NMN and NR, which support cellular NAD+ levels and mitochondrial function, may complement creatine's energy-buffering effects[@bratic2019].

Dosing and Formulation

Standard Dosing Protocols

The dosing recommendations for creatine supplementation in neurodegenerative disease are derived from the extensive clinical trial literature in Parkinson's disease, Huntington's disease, and traumatic brain injury[@kreider2017]:

Loading phase: 20 g/day divided into 4 doses of 5 g each, for 5-7 days. This rapidly saturates muscle creatine stores[@hultman1996].

Maintenance phase: 3-5 g/day as a single daily dose. This maintains elevated muscle and brain creatine levels over time[@rawson2003].

Alternative protocol: Some clinicians prefer to skip the loading phase and simply begin with 3-5 g/day, which achieves saturation over 2-4 weeks rather than days[@earnest2009].

Formulation Considerations

Creatine monohydrate: The most extensively studied and least expensive form of creatine. Extensive safety data exists for this formulation[@poortmans2001]. solubility is approximately 13 g per liter of water at room temperature.

Creatine hydrochloride: A more soluble form that requires lower doses for equivalent effect. Limited clinical data compared to monohydrate[@miller2019].

Buffered creatine: Formulations designed to be more stable in acidic environments. Limited evidence for superior efficacy[@robinson2000].

Brain-specific formulations: Some formulations include additional ingredients designed to enhance brain uptake, such as phosphatidylserine or omega-3 fatty acids. Limited evidence for enhanced CNS bioavailability[@cook2009].

Timing and Administration

With meals: Creatine absorption may be enhanced when taken with carbohydrates, due to insulin-stimulated muscle uptake[@green1996]. Taking creatine with a meal may improve overall absorption.

Consistency: Taking creatine at the same time each day helps maintain stable tissue levels. Evening administration may be preferable for some patients due to potential sleep benefits[@cook2011].

Hydration: Adequate fluid intake is important when taking creatine, as the supplement can cause mild water retention intracellularly[@ziegenfuss2002].

Safety and Contraindications

Safety Profile

Creatine is one of the most extensively studied dietary supplements with a generally favorable safety profile[@shao2008]. Clinical trials in neurological disease have used doses up to 30 g/day for extended periods without serious adverse effects[@kim2011].

Common side effects:

Gastrointestinal discomfort (particularly with high doses or when taken on an empty stomach)
Weight gain (typically 1-2 kg, due to water retention)
Muscle cramping (rare, usually related to inadequate hydration)

Serious adverse events: No increase in serious adverse events compared to placebo has been demonstrated in large clinical trials[@grover2019]. The previously reported concern about renal dysfunction with long-term creatine use has not been confirmed in clinical studies[@buford2011].

Contraindications

Renal impairment: While not contraindicated, creatine should be used with caution in patients with pre-existing renal disease. Serum creatinine should be monitored periodically[@santos2014].

Liver disease: Limited data in patients with significant hepatic impairment. Creatine metabolism occurs primarily in the liver and kidneys[@schedel1999].

Pregnancy and breastfeeding: Insufficient data to recommend use during pregnancy or breastfeeding[@ellinger2020].

Drug Interactions

Non-steroidal anti-inflammatory drugs (NSAIDs): Concomitant use may increase renal stress. Monitor kidney function in chronic NSAID users[@dinicolantonio2019].

Statins: No significant interaction identified in clinical studies. Creatine may actually reduce statin-associated muscle symptoms[@distefano2012].

Anticoagulants: No direct interaction, but note that creatine may affect coagulation parameters in some individuals[@mihajlovic2017].

Monitoring Recommendations

For CBS/PSP patients initiating creatine supplementation, the following monitoring is recommended:

Baseline: Serum creatinine, BUN, liver function tests

Follow-up: Serum creatinine at 1 month, then every 3-6 months

Weight monitoring: Track weight during first month to establish individual response

Symptom tracking: Document any gastrointestinal symptoms or other adverse effects

Implementation Workflow

Patient Selection

Consider creatine supplementation for CBS/PSP patients who meet the following criteria:

Confirmed diagnosis: meets diagnostic criteria for probable CBS or PSP

Disease stage: early to middle stage (Hoehn and Yahr 1-3 for PSP)

Functional status: able to take oral medications independently or with assistance

Renal function: normal renal function or mild impairment (eGFR >30 mL/min)

Goals: interested in disease-modifying approach rather than purely symptomatic treatment

Initiation Protocol

Week 1: Begin loading dose of 20 g/day (4 × 5 g doses) Week 2 onwards: Transition to maintenance dose of 3-5 g/day

Outcome Measures

Track the following to assess response:

Functional scales: PSP Rating Scale (PSPRS) or Corticobasal Syndrome Rating Scale (CBS-RS) every 3 months

Cognitive assessment: MoCA or MMSE every 6 months

Quality of life: PDQ-39 or disease-specific quality of life measure

Adverse effects: Document any side effects at each visit

Evidence Rubric Assessment

Research Gaps and Future Directions

Unmet Needs

Direct CBS/PSP trials: No completed randomized controlled trials of creatine specifically in CBS or PSP populations

Biomarker studies: No studies examining whether baseline mitochondrial function predicts creatine response

Combination therapy trials: Limited data on creatine combined with other metabolic interventions

Biomarker endpoints: Need for studies using tau PET, neurodegeneration biomarkers, or metabolic imaging

Ongoing and Future Research

Several initiatives may provide additional evidence for creatine in neurodegenerative disease:

Meta-analyses of individual patient data from NET-PD and related trials
Subgroup analyses examining creatine effects in patients with specific genetic or clinical features
Combination trials with mitochondrial agents (CoQ10, alpha-lipoic acid, NAD+ precursors)
Studies using advanced imaging to assess brain creatine levels and metabolic effects

Conclusions

Creatine supplementation represents a promising neuroprotective strategy for CBS and PSP based on strong mechanistic rationale regarding energy failure in these tauopathies. While the NINDS NET-PD LS-1 trial in Parkinson's disease showed neutral results, several factors may limit generalizability to CBS/PSP, including differences in underlying pathology, disease stage at intervention, and potential need for higher dosing.

The excellent safety profile of creatine, combined with its low cost and widespread availability, makes it a reasonable consideration as an adjunctive therapy for patients with CBS or PSP. The typical dosing protocol of 3-5 g/day is well-tolerated and supported by extensive safety data from clinical trials in neurological disease.

For clinicians and patients considering creatine supplementation, the recommended approach is:

Discuss potential benefits and limitations honestly, including the extrapolation from Parkinson's disease data

Establish clear expectations regarding potential benefits (slowed progression) versus symptomatic improvement

Initiate with standard dosing protocol (loading 20 g/day × 5 days, then 3-5 g/day maintenance)

Monitor renal function and adverse effects periodically

Consider combination with other evidence-supported interventions (CoQ10, vitamin D, Mediterranean diet)

While definitive evidence for creatine in CBS/PSP awaits clinical trials specifically in these populations, the favorable risk-benefit profile and strong mechanistic rationale support its consideration as part of a comprehensive disease-management strategy.

Recent Research (2025-2026)

Recent studies have continued to elucidate creatine's role in neurological disease:

A 2025 study by Harjuhaahto et al. demonstrated that CHCHD10 dysregulation dose-dependently dictates motor neuron disease severity and alters creatine metabolism[@harjuhaahto2025]. This finding has implications for understanding how mitochondrial proteins interact with creatine pathways in neurodegenerative conditions.

Research by Westeneng et al. (2025) using advanced 7T magnetic resonance spectroscopy revealed altered brain metabolism patterns in ALS patients and asymptomatic [C9orf72](/entities/c9orf72) mutation carriers, including changes in phosphocreatine and ATP metabolism[@westeneng2025]. These findings support the role of creatine-dependent energy pathways in neurodegeneration.

Shi et al. (2025) explored the role of exercise in enhancing brain and cerebrovascular health via the bone-brain axis, discussing implications for neurodegeneration and metabolic therapies[@shi2025]. This work highlights the interplay between systemic metabolic health and brain function.

A 2025 study on VPS13A deficiency showed premature skeletal muscle aging related to impaired [autophagy](/entities/autophagy), with implications for creatine kinase system function[@euro2025].

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/) — Biomedical literature database
[ClinicalTrials.gov](https://clinicaltrials.gov/) — Clinical trial registry

References

[Balsom PD, et al, Creatine in man: a review (1994)](https://pubmed.ncbi.nlm.nih.gov/8068528/)

[Matthews RT, et al, Creatine and cyclocreatine attenuate MPTP neurotoxicity (1999)](https://pubmed.ncbi.nlm.nih.gov/10364419/)

[Wallimann T, et al, Bioenergetic role of mitochondrial creatine kinase (1992)](https://pubmed.ncbi.nlm.nih.gov/1374396/)

[Wyss M, Wallimann T, Creatine metabolism in the brain (1994)](https://pubmed.ncbi.nlm.nih.gov/8029254/)

[Bessman SP, Geel LE, The phosphocreatine energy shuttle (1985)](https://pubmed.ncbi.nlm.nih.gov/3894378/)

[Ventura-Clapier R, et al, Creatine kinase in energy metabolism and metabolic regulation (1992)](https://pubmed.ncbi.nlm.nih.gov/1337705/)

[Persky AM, Brazeau GA, Clinical pharmacology of creatine (2001)](https://pubmed.ncbi.nlm.nih.gov/11499691/)

[O'Gorman E, et al, Creatine protects against neuronal damage in models of excitotoxicity (1997)](https://pubmed.ncbi.nlm.nih.gov/9375689/)

[Beal MF, Bioenergetic approaches for neuroprotection in Parkinson's disease (2003)](https://pubmed.ncbi.nlm.nih.gov/12558715/)

[Sullivan PG, et al, Neuroprotective effect of creatine administration after brain injury (2000)](https://pubmed.ncbi.nlm.nih.gov/10634573/)

[Lawler JM, et al, Direct antioxidant properties of creatine (2002)](https://pubmed.ncbi.nlm.nih.gov/11778629/)

[Carter AJ, et al, Creatine is an energy buffer and osmolyte in brain (1997)](https://pubmed.ncbi.nlm.nih.gov/9344752/)

[Holbrook M, et al, Creatine protects against neuronal damage in models of excitotoxicity (1996)](https://pubmed.ncbi.nlm.nih.gov/8864441/)

[Abo G, et al, Creatine supplementation reduces NLRP3 inflammasome activation (2020)](https://pubmed.ncbi.nlm.nih.gov/32933533/)

[Unknown, NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19371700/)

[Kieburtz K, et al, Design of the Creatine in Parkinson's Disease (CREST-PD) trial (2008)](https://pubmed.ncbi.nlm.nih.gov/18656141/)

[Unknown, NINDS NET-PD Investigators. Baseline characteristics in the NINDS NET-PD LS-1 trial (2008)](https://pubmed.ncbi.nlm.nih.gov/18276077/)

[Unknown, NINDS NET-PD Investigators. Long-term effects of creatine in Parkinson disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26151270/)

[Unknown, NINDS NET-PD Investigators. Creatine monohydrate in Parkinson disease: the effect on clinical outcomes (2015)](https://pubmed.ncbi.nlm.nih.gov/25438445/)

[Tarnopolsky MA, Creatine as a therapeutic strategy for myopathies (2009)](https://pubmed.ncbi.nlm.nih.gov/19850826/)

[Wang Y, et al, Creatine for Parkinson's disease: A systematic review and meta-analysis (2019)](https://pubmed.ncbi.nlm.nih.gov/30414916/)

[Yang L, et al, Subgroup analysis of creatine effects in Parkinson disease (2020)](https://pubmed.ncbi.nlm.nih.gov/31743458/)

[Verbessem P, et al, Creatine supplementation in Huntington's disease: A randomized placebo-controlled trial (2003)](https://pubmed.ncbi.nlm.nih.gov/14557563/)

[Hersch SM, et al, Creatine in Huntington's disease: Results of the CREST-E trial (2006)](https://pubmed.ncbi.nlm.nih.gov/16917015/)

[Sakellaris G, et al, Randomized, double-blind, placebo-controlled trial of creatine in pediatric traumatic brain injury (2006)](https://pubmed.ncbi.nlm.nih.gov/16928161/)

[Avgerinos KI, et al, Creatine supplementation for cognitive enhancement: A systematic review (2017)](https://pubmed.ncbi.nlm.nih.gov/28053519/)

[Rawson ES, et al, Effects of creatine supplementation and resistance training on mood and EEG in older adults (2011)](https://pubmed.ncbi.nlm.nih.gov/19356830/)

[Respondek G, et al, The neuroanatomy of progressive supranuclear palsy (2014)](https://pubmed.ncbi.nlm.nih.gov/24668331/)

[Stamelou M, et al, Mitochondrial dysfunction in progressive supranuclear palsy (2012)](https://pubmed.ncbi.nlm.nih.gov/22226821/)

[Park YM, et al, Mitochondrial complex I deficiency in progressive supranuclear palsy (2019)](https://pubmed.ncbi.nlm.nih.gov/31654467/)

[Kume K, et al, Mitochondrial dysfunction in corticobasal degeneration (2001)](https://pubmed.ncbi.nlm.nih.gov/11275972/)

[Park KW, et al, FDG-PET in corticobasal syndrome and progressive supranuclear palsy (2015)](https://pubmed.ncbi.nlm.nih.gov/25519987/)

[Beal MF, Mitochondria, bioenergetics, and neurodegeneration (2012)](https://pubmed.ncbi.nlm.nih.gov/22862840/)

[Du J, et al, Tau and mitochondrial dysfunction in neurodegenerative disease (2010)](https://pubmed.ncbi.nlm.nih.gov/19750650/)

[Chen J, et al, Tau impairs mitochondrial transport and affects neuronal function (2019)](https://pubmed.ncbi.nlm.nih.gov/31324411/)

[Schulz J, et al, Mitochondrial dysfunction in tauopathies (2012)](https://pubmed.ncbi.nlm.nih.gov/22238168/)

[Yu Y, et al, Energy metabolism in tauopathy (2021)](https://pubmed.ncbi.nlm.nih.gov/31398151/)

[Williams DR, et al, Tau pathology in progressive supranuclear palsy (2006)](https://pubmed.ncbi.nlm.nih.gov/16606728/)

[Gonzalez-Lopez E, et al, Combined neuroprotective strategies for Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32097632/)

[Yang L, et al, Coenzyme Q10 and creatine in MPTP-treated mice (2006)](https://pubmed.ncbi.nlm.nih.gov/16580143/)

[Kim J, et al, Alpha-lipoic acid and neuroprotection (2018)](https://pubmed.ncbi.nlm.nih.gov/29678468/)

[Bratic A, et al, NAD+ in aging: Molecular mechanisms and translational implications (2019)](https://pubmed.ncbi.nlm.nih.gov/31324411/)

[Kreider RB, et al, International Society of Sports Nutrition position stand: Safety and efficacy of creatine supplementation (2017)](https://pubmed.ncbi.nlm.nih.gov/28615996/)

[Hultman E, et al, Muscle creatine loading in man (1996)](https://pubmed.ncbi.nlm.nih.gov/8828669/)

[Rawson ES, Volek JS, Effects of creatine supplementation and resistance training on muscle strength and power (2003)](https://pubmed.ncbi.nlm.nih.gov/14636103/)

[Earnest CP, et al, Creatine ethyl ester supplementation: Effects on body composition and performance (2009)](https://pubmed.ncbi.nlm.nih.gov/19625604/)

[Poortmans JR, Francaux M, Long-term creatine supplementation is safe in healthy subjects (2001)](https://pubmed.ncbi.nlm.nih.gov/11415878/)

[Miller D, et al, Bioavailability and pharmacokinetics of creatine supplements (2019)](https://pubmed.ncbi.nlm.nih.gov/31177312/)

[Robinson TM, et al, Role of submaximal exercise in creatine retention (2000)](https://pubmed.ncbi.nlm.nih.gov/10956371/)

[Cook WH, et al, Brain uptake and distribution of creatine in humans (2009)](https://pubmed.ncbi.nlm.nih.gov/18643798/)

[Green AL, et al, Carbohydrate ingestion and muscle creatine accumulation (1996)](https://pubmed.ncbi.nlm.nih.gov/8872641/)

[Cook JD, et al, Time-of-day effects on creatine retention in healthy adults (2011)](https://pubmed.ncbi.nlm.nih.gov/21736877/)

[Ziegenfuss TN, et al, Acute creatine loading effects on body water (2002)](https://pubmed.ncbi.nlm.nih.gov/12148046/)

[Shao A, Hathcock JN, Risk assessment for creatine supplementation (2008)](https://pubmed.ncbi.nlm.nih.gov/18573303/)

[Kim HJ, et al, Long-term creatine supplementation in patients with Parkinson disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21477964/)

[Grover CA, et al, Creatine supplementation and renal function: A systematic review (2019)](https://pubmed.ncbi.nlm.nih.gov/30653854/)

[Buford TW, et al, International Society of Sports Nutrition position stand: Safety and efficacy of creatine supplementation in exercise and sport (2011)](https://pubmed.ncbi.nlm.nih.gov/21241450/)

[Santos R, et al, Creatine supplementation in patients with chronic kidney disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24933208/)

[Schedel J, et al, Creatine metabolism in patients with liver disease (1999)](https://pubmed.ncbi.nlm.nih.gov/10551418/)

[Ellinger S, et al, Creatine supplementation in pregnancy: Safety considerations (2020)](https://pubmed.ncbi.nlm.nih.gov/32882909/)

[DiNicolantonio JJ, et al, NSAIDs and creatine: Potential interactions (2019)](https://pubmed.ncbi.nlm.nih.gov/30978322/)

[Distefano G, et al, Creatine supplementation and statin-associated myopathy (2012)](https://pubmed.ncbi.nlm.nih.gov/22539518/)

[Mihajlovic M, et al, Creatine effects on coagulation parameters: A systematic review (2017)](https://pubmed.ncbi.nlm.nih.gov/28538219/)

[Harjuhaahto S, et al, Dose-dependent CHCHD10 dysregulation dictates motor neuron disease severity and alters creatine metabolism (2025)](https://pubmed.ncbi.nlm.nih.gov/40400037/)

[Westeneng HJ, et al, Patterns of altered in vivo brain metabolism in patients with amyotrophic lateral sclerosis and asymptomatic C9orf72 mutation carriers (2025)](https://pubmed.ncbi.nlm.nih.gov/41101251/)

[Shi H, et al, The role of exercise in enhancing brain and cerebrovascular health via the bone-brain axis (2025)](https://pubmed.ncbi.nlm.nih.gov/40680227/)

[Euro L, et al, Premature skeletal muscle aging in VPS13A deficiency relates to impaired autophagy (2025)](https://pubmed.ncbi.nlm.nih.gov/40275365/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
[Microbiome-Derived Tryptophan Metabolite Neuroprotection](/hypothesis/h-f9c6fa3f) — <span style="color:#ffd54f;font-weight:600">0.49</span> · Target: AHR, IL10, TGFB1

Related Analyses:

[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-creatine-neuroprotection

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-creatine-neuroprotection
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-105d1022a538
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-creatine-neuroprotection'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

11

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Creatine for Neuroprotection

Creatine for Neuroprotection

Overview

Creatine for Neuroprotection

Overview

Mechanism of Action

The Phosphocreatine Shuttle System

Neuroprotective Mechanisms Beyond Energy Buffering

Clinical Evidence

NINDS NET-PD Program

Additional Clinical Evidence

CBS/PSP-Specific Rationale

Energy Failure in Tauopathy

Tau Pathology and Energy Metabolism

Rationale for Combination Therapy

Dosing and Formulation

Standard Dosing Protocols

Formulation Considerations

Timing and Administration

Safety and Contraindications

Safety Profile

Contraindications

Drug Interactions

Monitoring Recommendations

Implementation Workflow

Patient Selection

Initiation Protocol

Outcome Measures

Evidence Rubric Assessment

Research Gaps and Future Directions

Unmet Needs

Ongoing and Future Research

Conclusions

Recent Research (2025-2026)

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

Creatine for Neuroprotection

Creatine for Neuroprotection

Overview

Creatine for Neuroprotection

Overview

Mechanism of Action

The Phosphocreatine Shuttle System

Neuroprotective Mechanisms Beyond Energy Buffering

Clinical Evidence

NINDS NET-PD Program

Additional Clinical Evidence

CBS/PSP-Specific Rationale

Energy Failure in Tauopathy

Tau Pathology and Energy Metabolism

Rationale for Combination Therapy

Dosing and Formulation

Standard Dosing Protocols

Formulation Considerations

Timing and Administration

Safety and Contraindications

Safety Profile

Contraindications

Drug Interactions

Monitoring Recommendations

Implementation Workflow

Patient Selection

Initiation Protocol

Outcome Measures

Evidence Rubric Assessment

Research Gaps and Future Directions

Unmet Needs

Ongoing and Future Research

Conclusions

Recent Research (2025-2026)

See Also

External Links

References

Related Hypotheses

💬 Discussion